Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angiodysplasia | 1 | 2017 | 22 | 0.560 |
Why?
|
Nursing Staff | 1 | 2017 | 113 | 0.540 |
Why?
|
Cannabinoids | 1 | 2019 | 173 | 0.540 |
Why?
|
Skin Diseases | 1 | 2022 | 1099 | 0.430 |
Why?
|
Gastroenterology | 1 | 2017 | 588 | 0.360 |
Why?
|
Colitis | 1 | 2019 | 1244 | 0.350 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2017 | 1126 | 0.340 |
Why?
|
Crohn Disease | 1 | 2022 | 2293 | 0.330 |
Why?
|
Endoscopy | 1 | 2017 | 1857 | 0.290 |
Why?
|
Heart-Assist Devices | 1 | 2017 | 1292 | 0.270 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 3941 | 0.230 |
Why?
|
Students, Medical | 1 | 2017 | 1962 | 0.230 |
Why?
|
Leukocyte L1 Antigen Complex | 1 | 2022 | 94 | 0.200 |
Why?
|
Interleukin-23 | 1 | 2022 | 201 | 0.180 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2022 | 887 | 0.130 |
Why?
|
Vomiting | 1 | 2019 | 655 | 0.130 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2017 | 2768 | 0.120 |
Why?
|
Heart Failure | 1 | 2017 | 11857 | 0.100 |
Why?
|
Syndrome | 1 | 2019 | 3278 | 0.100 |
Why?
|
Anticoagulants | 2 | 2017 | 4840 | 0.100 |
Why?
|
Blood Coagulation | 1 | 2017 | 1162 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1575 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2017 | 1395 | 0.090 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2011 | 85 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3854 | 0.090 |
Why?
|
Prosthesis Design | 1 | 2017 | 2126 | 0.090 |
Why?
|
Teaching | 1 | 2017 | 1174 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2772 | 0.080 |
Why?
|
Receptor, Adenosine A2B | 1 | 2008 | 34 | 0.080 |
Why?
|
Warfarin | 1 | 2017 | 1493 | 0.080 |
Why?
|
Receptor, Adenosine A2A | 1 | 2008 | 129 | 0.080 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2082 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2239 | 0.070 |
Why?
|
Recovery of Function | 1 | 2017 | 2994 | 0.070 |
Why?
|
Aspirin | 1 | 2017 | 3139 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2022 | 22293 | 0.060 |
Why?
|
Treatment Outcome | 2 | 2022 | 65409 | 0.050 |
Why?
|
Inflammation | 1 | 2022 | 10865 | 0.050 |
Why?
|
Killer Cells, Natural | 1 | 2011 | 2209 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3858 | 0.050 |
Why?
|
Clinical Competence | 1 | 2017 | 4841 | 0.050 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2008 | 1797 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2008 | 2326 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2011 | 2260 | 0.040 |
Why?
|
Risk Assessment | 1 | 2017 | 24311 | 0.030 |
Why?
|
Humans | 5 | 2022 | 768451 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2022 | 81834 | 0.030 |
Why?
|
Pemphigus | 1 | 2011 | 108 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 74915 | 0.020 |
Why?
|
Adenosine-5'-(N-ethylcarboxamide) | 1 | 2008 | 16 | 0.020 |
Why?
|
Adenosine A2 Receptor Agonists | 1 | 2008 | 31 | 0.020 |
Why?
|
Mice, Inbred DBA | 1 | 2008 | 624 | 0.020 |
Why?
|
Animals | 2 | 2017 | 169418 | 0.020 |
Why?
|
Extracellular Space | 1 | 2008 | 565 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2008 | 1355 | 0.010 |
Why?
|
Cyclic AMP | 1 | 2008 | 1468 | 0.010 |
Why?
|
Adenosine | 1 | 2008 | 816 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2008 | 3169 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2008 | 5495 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2008 | 17149 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2008 | 22365 | 0.010 |
Why?
|
Mice | 1 | 2008 | 82045 | 0.000 |
Why?
|
Concepts
(62)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_